title: Esophageal pemphigus vulgaris with carcinoma: postoperative steroid therapy based on pemphigus-related antibodies.
abstract: A 71-year-old man had been treated as an outpatient for pemphigus vulgaris. Endoscopic examination disclosed an ulcerated lesion in the middle of the esophagus. A biopsy specimen was diagnosed pathologically as squamous cell carcinoma. At surgery, the esophageal mucosa beyond the resection margin appeared edematous and blistered. We carried out anastomosis with sutures rather than staples at the site where the epithelium was least damaged, to minimize likelihood of anastomotic breakdown from poor blood flow. Histopathologic examination of the resected specimen additionally showed blisters and acantholytic cells throughout the esophageal mucosa, so esophageal pemphigus was diagnosed in addition to carcinoma. The patient's general condition deteriorated from worsening of pemphigus. We initiated steroid therapy, making adjustments according to changes in titers of anti-intercellular bridge antibody and antibodies to the cell adhesion molecules (desmoglein 1 and 3). Fever and extensive blistering subsided dramatically, and the patient was discharged in good condition on hospital day 103. When performing esophagectomy in the presence of esophageal pemphigus, the anastomosis must be fashioned cautiously because any mechanical stress can abrade the friable edematous esophageal mucosa. While steroid therapy is known to be effective for pemphigus vulgaris, our findings indicate that in patients with postoperative deterioration of their general condition, marked improvement can be obtained by using antibody titers to guide timing and dose in steroid administration.
authors.affiliation: Department of Surgical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. osamu480111@nifty.com
authors.forename: O
authors.initials: O
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Okushiba
authors.forename: S
authors.initials: S
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Morikawa
authors.forename: S
authors.initials: S
authors.lastname: Hirano
authors.forename: M
authors.initials: M
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Shichinohe
authors.forename: T
authors.initials: T
authors.lastname: Hara
authors.forename: Y
authors.initials: Y
authors.lastname: Kawarada
authors.forename: K
authors.initials: K
authors.lastname: Saito
authors.forename: M
authors.initials: M
authors.lastname: Takeuchi
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000150:complications* / Q000473:pathology / Q000601:surgery; D051182:Desmogleins / Q000276:immunology / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000150:complications* / Q000473:pathology / Q000601:surgery; D016629:Esophagectomy; D006801:Humans; D008297:Male; D010392:Pemphigus / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D001323:Autoantibodies; D051182:Desmogleins; D011239:Prednisolone